Supratik Basu

11PUBLICATIONS
48CO-AUTHORS
Ngā rongoā me ngā whakamaimoa o te Māori (Māori medicine and treatments)Cancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Aug 24, 2026
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.

|Feb 27, 2025
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes.

Thierry Facon, Philippe Moreau, Katja Weisel

|Feb 05, 2025
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.

Saad Z Usmani, Thierry Facon, Vania Hungria

|Jan 15, 2025
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study.

Philippe Moreau, Thierry Facon, Saad Z Usmani

|Dec 18, 2024
The UK consensus supporting effective introduction of novel treatments for multiple myeloma in the National Health Service.

Rakesh Popat, Supratik Basu, Sarah Henshaw

|Dec 20, 2023
Determinants of durable humoral and T cell immunity in myeloma patients following COVID-19 vaccination.

Clement Twumasi, Sally Moore, Ross Sadler

Pageof 2

Frequent Collaborators

7 joint publications

Saad Z Usmani

6 joint publications

Nizar J Bahlis

5 joint publications

Aurore Perrot

4 joint publications

Shaji Kumar